Skip to content
value.today

NextCure, Inc. vs Regenxbio Inc.

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Regenxbio Inc. is the larger company by market value: $513 M against $30 M for NextCure, Inc., 17 times as much (market caps of Oct 30, 2026 for NextCure, Inc. and Oct 6, 2026 for Regenxbio Inc.).
  • Both made a net loss: $56 M for NextCure, Inc. and $194 M for Regenxbio Inc.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

02959881172020202120222023202420252026NextCure, Inc. 2Regenxbio Inc. 35

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$0B$0B$0B$0B201720182019202020212022202320242025NextCure, Inc. $0BRegenxbio Inc. $0B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureNextCure, Inc.
NXTC · #23,090 in the world
Regenxbio Inc.
RGNX · #12,415 in the world
Profile
Country🇺🇸 USA🇺🇸 USA
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology
Founded——
Size
Market cap$30 M$513 M
Revenue—$170 M
Net income$-56 M▲ best$-194 M
Employees—372
Valuation
Price to sales—3.3×
Price to book0.9×5.0×
Free cash flow yield-138.0%-24.6%▲ best
Profitability
Operating margin—-94.6%
Net margin—-113.8%
Return on equity-111.2%-107.0%▲ best
Growth
Revenue growth—104.5%
Revenue growth, 3 years a year—14.8%
Cash
Free cash flow margin—-74.1%
Altman Z-score zone—distress
Data as ofMarket cap Oct 2026; ratios FY2025Market cap Oct 2026; ratios FY2025

Questions and answers#

Which is bigger, NextCure, Inc. or Regenxbio Inc.?

Regenxbio Inc. is the larger company by market value: $513 M against $30 M for NextCure, Inc., 17 times as much (market caps of Oct 30, 2026 for NextCure, Inc. and Oct 6, 2026 for Regenxbio Inc.).

Which makes more money, NextCure, Inc. or Regenxbio Inc.?

Both made a net loss: $56 M for NextCure, Inc. and $194 M for Regenxbio Inc.